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ABSTRACT
Objectives: Nephron-sparing surgery has emerged as the
treatment of choice for the incidentally detected small
renal mass, especially those less than 4 cm in size. We
describe our technique and experience with the laparo-
scopic excision of these lesions.
Methods: Between June 2001 and October 2003, 20 pa-
tients underwent nephron-sparing surgery at our institu-
tion. Twenty-one laparoscopic partial nephrectomy pro-
cedures were performed. All tumors were detected
incidentally by cross-sectional imaging. All patients had a
solid renal mass or a complex cystic renal mass of Bosniak
category III or greater. All solid tumors were exophytic
and less than 4cm in diameter. Both transperitoneal and
retroperitoneal approaches were used. Hemostasis was
achieved without hilar control in 20 of the 21 cases.
Results: Twenty renal units were approached transperi-
toneally, and 1 retroperitoneally. Mean tumor size was 2.6
cm (range, 1.2 to 4). Mean estimated blood loss was 211
mL (range, 50 to 500), and mean operative time was 165
minutes. Pathology revealed renal cell carcinoma in 14
(70%). No intraoperative complications occurred. Two
patients required blood transfusions postoperatively.
Conclusion: Carefully selected patients with small, exo-
phytic renal masses can safely undergo laparoscopic ex-
cision. When achievable, this procedure can be a more
logical alternative to ablative techniques for the minimally
invasive management of such lesions.
Key Words: Nephron sparing, Laparoscopic, Partial ne-
phrectomy, Ablative, Kidney.
INTRODUCTION
Nephron-sparing surgery is indicated for imperative indi-
cations, such as renal tumor in an anatomically or func-
tionally solitary kidney or in patients with bilateral syn-
chronous tumors. Relative indications include those
patients with a solitary renal mass where contralateral
function is compromised or in patients at risk for devel-
oping tumors in the contralateral kidney. Long-term re-
sults show disease-free survival comparable to that with
radical nephrectomy, when compared stage for stage.1
The goal is to preserve renal function without compro-
mising tumor control. Today, nephron-sparing surgery
can be viewed as the standard of care for tumors less than
4cm in size that are amenable to partial nephrectomy.1–4
This approach offers many advantages over the ablative
techniques of cryoablation, radiofrequency ablation, and
high-intensity focused ultrasound including more accurate
pathological diagnosis. Laparoscopic nephrectomy is rou-
tinely performed at many institutions worldwide follow-
ing its original description by Clayman in 1991.5 Since
then, primary series of laparoscopic partial nephrectomy
have been reported, and the procedure has been shown
to be safe with acceptable morbidity in carefully selected
patients.6–9
Laparoscopic excision of centrally located and larger tu-
mors with both hilar control and hypothermia has been
described by a few groups.10 However, laparoscopic par-
tial nephrectomy is a highly demanding procedure requir-
ing a high level of laparoscopic skill. To overcome the
technical hurdles, some have advocated minimally inva-
sive ablative approaches for the management of such
lesions including radiofrequency ablation, cryotherapy, or
high-intensity focused ultrasound. Yet in many patients,
these lesions are peripherally located and are easily ex-
cisable by the pure laparoscopic excision technique using
current hemostatic measures. This offers the theoretical
advantage of complete tumor removal and pathological
review. We report our experience on laparoscopic partial
nephrectomy in 21 cases.
METHODS
Between June 2001 and October 2003, 21 laparoscopic
partial nephrectomy procedures were performed at our
Department of Urology, Montefiore Medical Center, Albert Einstein College of
Medicine, Bronx, New York, USA (all authors).
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SCIENTIFIC PAPERinstitution in 20 patients by 2 surgeons. The medical
records were reviewed regarding operative techniques
and preliminary postoperative outcomes. Preoperative
evaluation included chest x-ray, complete blood count,
and metabolic panel, and either computed tomography
(CT) scan with intravenous (IV) contrast or magnetic res-
onance imaging (MRI) with gadolinium. Indications in-
cluded enhancing exophytic solid renal masses up to 4cm
in size with a normal contralateral kidney in 14, Bosniak
III complex renal cysts in 4, and bilateral synchronous
enhancing renal masses in one. All renal masses were
50% exophytic as evaluated by preoperative imaging.
The clinical parameters analyzed included patient demo-
graphics, location of tumor, pathological description, mar-
gin status, hemostatic techniques, preoperative serum he-
moglobin levels, operative time, estimated blood loss,
complications, length of stay, body mass index, and pain
score. Serum creatinine measurement were analyzed com-
paring preoperative, postoperative, and those on most
recent follow-up by using the Student t test. Average
postoperative pain scores were determined by using a
visual analog scale from 0 to 10, with 0 being no pain and
10 being most severe pain. The transperitoneal approach
was utilized in all but 1 patient, who was approached
retroperitoneally. Repeat imaging including computed to-
mography, renal ultrasound, or magnetic resonance im-
aging was available in 9 of the 14 patients with renal cell
carcinoma.
For the transperitoneal approach, patients were positioned
in a modified flank position, with a Veress needle used to
achieve pneumoperitoneum in the majority of cases. Four
port sites were used. With Gerota’s fascia incised, the renal
fat overlying the tumor was dissected free from the tumor
and sent to pathology. Once the kidney was mobilized for
optimum visualization of the lesion and kidney surface, the
tumor was enucleated or excised with a 0.5-cm margin via
wedge resection. The renal hilum was exposed in all cases,
but the renal vessels were clamped in only 1 patient due to
the depth of the lesion. A combination of electrocautery and
sharp dissection were used to excise the lesion. Following
removal of the tumor, frozen sections were sent from the
deep tumor crater and peripheral margin to ensure complete
resection. Bipolar electrocautery was used to fulgurate any
obvious bleeding vessels. Indigo carmine was given intrave-
nously to detect collecting system entry. The argon beam
coagulator was used to ‘paint’ the cut surface and Surgicel
(Ethicon, Somerville, NJ) was applied. The argon beam co-
agulator was used to ‘weld’ the Surgicel to the cut surface.
The hemostatic methods used changed as experience was
gained. Initially, the combined modalities of Surgicel and
the argon beam coagulator were used alone as described
above. As more cases were performed, one surgeon
gained experience with the addition of fibrin glue (Tisseel,
Baxter Healthcare Corp., Irvine, CA), while the other sur-
geon utilized the TissueLink radiofrequency coagulator
(TissueLink Medical, Dover, NH).
In the cases where fibrin glue was an additional hemo-
static aid, it was applied to the entire surface after the
Surgicel and argon beam coagulator in a relatively dry
field. In those cases where the TissueLink radiofrequency
coagulator was used, the TissueLink was able to help in
blunt dissection of the tumor from adjacent parenchyma,
although the majority of the tumor was dissected sharply.
Upon removal of the tumor, a combination of the Tis-
sueLink radiofrequency coagulator and argon beam co-
agulator were used to achieve hemostasis of the cut sur-
face. Once the results of the frozen biopsy specimens
were obtained, Surgicel was applied, and the argon beam
coagulator was used to ‘weld’ the Surgicel to the cut
surface. The collecting system was not entered in any
case. In the one patient where the renal hilum was
clamped, retrograde chilled saline was irrigated via a ure-
teral catheter.
The specimen was excised by using a laparoscopic scis-
sors, and the collecting system was closed primarily fol-
lowed by suture repair of the renal cortex. The specimen
was removed in a laparoscopic specimen bag. The insuf-
flating pressure was reduced to one half, and the cut
surface of the kidney was again examined to ensure he-
mostasis.
RESULTS
Twenty-one laparoscopic partial nephrectomy proce-
dures were performed in 20 patients, 14 men (66%) and
6 (33%) women. Patient characteristics and operative
variables are listed in Table 1. Patient ages ranged from
47 to 82 years. Five (26%) patients had evidence of
compromised renal function with serum creatinine lev-
els 1.5 mg/dL preoperatively. No statistical difference
existed between serum creatinine comparing preoper-
ative, postoperative, and on most recent follow-up.
Body mass index (BMI) ranged from 20.2 to 49.9 (me-
dian, 29.1; mean, 26.6). Three (14%) patients were se-
verely obese (BMI, 35 to 40), and one (5%) was mor-
bidly obese (BMI 40). Bilateral synchronous tumors
measuring 2.3 cm (right kidney) and 1.5cm (left kidney)
were removed in 1 patient. Removal of the tumors was
staged, with the larger lesion removed first, followed by
the remaining lesion 2 months later.
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roperitoneally in one. Hemostasis was achieved intraop-
eratively with at least 2 separate modalities. Thrombin
soaked Surgicel and argon beam coagulation were used in
all cases, with the TissueLink and fibrin glue added in the
latter part of the series and represented the preference of
the respective surgeon. Ischemia time was 40 minutes in
the one case where the hilum was clamped and chilled
saline was irrigated via a ureteral catheter. Preoperative,
postoperative, and serum creatinine at 14-month fol-
Table 1.
Patient Characteristics and Intraoperative Variables
Patient Sex Age
(years)
BMI* Tumor
Size
(cm)
Operative
Time
(minutes)
EBL*
(mL)
Hemostatic Methods Used Complications Mean
Pain
Score
LOS*
(days)
Follow-up
(months)
1 M 82 25.6 4 185 400 Argon beam, thrombin soaked
Surgicel
none 2 4 32
2 M 47 29.6 4 160 200 Argon beam, thrombin soaked
Surgicel
none 2 4 31
3 M 63 38.7 2.5 130 50 Argon beam, thrombin soaked
Surgicel
2 unit PRBC’s* 3 5 30
4 M 61 20.8 2.7 140 500 Argon beam, thrombin soaked
Surgicel
none 3 3 28
5 M 87 28.7 3 140 50 Fibrin glue, argon beam,
thrombin soaked Surgicel
none 0 2 23
6 M 74 37.2 2.3 165 100 Argon beam, thrombin soaked
Surgicel
none 0 4 22
7 M 74 37.2 1.5 190 50 Argon beam, thrombin soaked
Surgicel
none 2.5 3 20
8 M 58 38.6 2.5 210 100 Fibrin glue, argon beam,
thrombin soaked Surgicel
none 2 2 19
9 F 65 20.2 3 170 50 TissueLink, Argon beam,
thrombin soaked Surgicel
none 4.5 3 17
10 M 77 25.4 2 135 350 Fibrin glue, argon beam,
thrombin soaked Surgicel
none 2.3 3 15
11 M 48 28.1 3 180 200 TissueLink, Argon beam,
thrombin soaked Surgicel
none 5 3 13
12 F 60 27.4 3.4 220 400 Vessel clamp, Argon beam,
fibrin glue
none 2.7 5 12
13 F 52 49.9 4 185 50 TissueLink, Argon beam,
thrombin soaked Surgicel
none 2.5 3 12
14 M 68 25.5 1.5 180 300 Fibrin glue, argon beam,
thrombin soaked Surgicel
none 2 3 12
15 M 60 23.5 2.5 140 400 TissueLink, Argon beam,
thrombin soaked Surgicel
none 2 6 12
16 F 66 28.8 1.2 160 200 Fibrin glue, argon beam,
thrombin soaked Surgicel
none 1.2 4 11
17 M 79 22.5 2 160 500 Argon beam, thrombin soaked
Surgicel
2 unit PRBC’s* 2.3 2 9
18 M 59 25.1 1.6 94 50 TissueLink, Argon beam,
thrombin soaked Surgicel
none 4 2 9
19 F 78 23.6 1.2 120 50 Fibrin glue, argon beam,
thrombin soaked Surgicel
none 1 3 7
20 M 58 27.8 3.5 195 200 TissueLink, Argon beam,
thrombin soaked Surgicel
none 1.4 3 7
Mean 65.8 29.2 2.63 163 210.0 2.3 3.4 9.7
Median 65 27.40 2.50 160 200 2.3 3 7
*BMIbody mass index; EBLestimated blood loss; LOSlength of stay; PRBCpacked red blood cells.
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spectively. The collecting system was not entered in this
case.
Pathologic variables are presented in Table 2. Fourteen
(67%) of the resected tumors were renal cell cancer, 2
(10%) were oncocytomas, and 4 (19%) were other diag-
noses as listed. Most renal cell carcinomas were of low
grade (I-II, 79%).
Margin status by frozen section was negative for all spec-
imens. Margin status on final pathology was also negative.
No intraoperative complications occurred. Two patients
required blood transfusions (2 units) postoperatively. In
both cases, only argon beam coagulation and thrombin
soaked Surgicel were used for hemostasis. In the cases
where another hemostatic aid was added (fibrin glue or
TissueLink), no bleeding complications occurred. No
other complications occurred. Length of stay ranged from
2 days to 6 days (mean, 3.4; median, 3). The postoperative
pain score was calculated as the average of the pain scores
from postoperative day number one. The mean (median)
average postoperative pain score was 2.2 (2.3) (range, 0 to
5). The majority of patients were discharged on postop-
erative day #2. Patient #12 had a longer length of stay to
allow sequential removal of a ureteral stent, Foley cathe-
ter, and Jackson Pratt drain, with interval observation for
potential urine leak, which did not occur. Patient #15
incurred a longer length of stay for medical reasons. Fol-
low-up imaging available in 9 of the 14 patients with renal
cell carcinoma (mean, 18 months; median, 21 months;
range, 5 to 30) revealed no evidence of recurrence.
Data regarding time to convalescence, time until back to
normal routine, and time to full recovery were not ac-
quired.
DISCUSSION
Nephron-sparing surgery in the setting of a normal con-
tralateral kidney is a well-established treatment modality
for suspected renal cell cancer with proven safety and
efficacy.3 Fundamentals of nephron-sparing surgery in-
clude tissue removal under direct vision with adequate
tumor-free margin and assessment of margin status intra-
operatively. Use of novel techniques of hemostasis when
performing laparoscopic partial nephrectomy have been
described; vessel clamping to maintain a bloodless field
although feasible, is technically difficult.7 Hemostasis by
coagulation can be achieved laparoscopically; however,
the depth of coagulation cannot be predicted, and a risk
exists of secondary bleeding due to necrosis of the coag-
ulated surface area. Also, hypothermia via the laparo-
scopic approach, although feasible,10 is a hurdle not yet
overcome, limiting the acceptable ischemia time after
which renal function may be significantly compromised.
The transperitoneal and retroperitoneal approaches to
laparoscopic partial nephrectomy were first described by
Winfield in 19936 and by Gill in 1994.9 Careful patient
selection for laparoscopic nephron-sparing surgery is
mandatory for both safety and potential cure. All tumors in
our series were exophytic and amenable to laparoscopic
excision. A ureteral stent was not placed routinely be-
cause major disruption of the collecting system was not
anticipated. No complications occurred related to urinary
leakage or fistula formation. A retroperitoneal approach
was chosen in one patient. This approach was selected in
this case due to the posterior location of the renal tumor
and past surgical history of abdominal surgery.
Table 2.
Pathologic Variables
Histology Number (%)
Renal Cell Cancer 14 (70)
Clear Cell, TNM* Stage pT1NxMx 10 (50)
Histologic Grade†
I4
II 5
III 1
IV 0
Chromophobe, TNM* Stage pT1NxMx 2 (10)
Histologic Grade†
III 1
IV 1
Papillary, TNM* Stage pT1NxMx 2 (10)
Histologic Grade†
I1
II 1
Oncocytoma 2 (10)
Other Diagnoses 4 (20)
Lymphoma 1
Cystic Nephroma 1
Leiomyoma 1
Benign parenchyma with cysts 1
*Tumor, node, metastasis staging as put forth by the American
Joint Committee on Cancer.
†Based on Fuhrman grading system.
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with morbid obesity. Prior reports have demonstrated that
the laparoscopic approach is more beneficial in obese
patients, enabling a significant decrease in length of hos-
pitalization, analgesic requirements, and decreased
wound complications.11
Currently, no “standard” technique exists for laparoscopic
partial nephrectomy. During the course of the study, the
techniques used to achieve hemostasis evolved as expe-
rience was gained. The Harmonic scalpel has been shown
to be inadequate when used alone to achieve adequate
hemostasis for controlling renal parenchymal bleeding. It
was used in dissection but not as a hemostatic tool in our
study.7,12
Fibrin glue (Tisseel, Baxter Healthcare Corp., Irvine, CA)
has been shown to be effective for both hemostasis in
general and as a urinary tract sealant.13 Its successful
application for laparoscopic nephron-sparing surgery as a
hemostatic aid has been reported.6,14 No bleeding com-
plications occurred with the use of fibrin glue in our
series. Other means of hemostasis, as described, were
used to develop a relatively dry field for the fibrin sealant
to promote the final steps of the coagulation cascade. It is
not effective for high-pressure bleeding, but will prevent
oozing from renal parenchyma. The TissueLink Floating
Ball (TissueLink Medical, Dover, NH) incorporates a wa-
ter-cooled, high-density, monopolar current. Saline irri-
gates the floating ball to avoid excessive increase in tissue
impedance to produce a more predictable pattern of co-
agulation than conventional monopolar current at greater
depths of the parenchyma, reducing the risk of secondary
bleeding from necrosis of the coagulation bed. Resection
with this device is slower than resection with vascular
control and has an associated learning curve that must be
overcome to prevent inadequate treatment.15
The only complication encountered in this series was
bleeding, requiring 2 units of packed, red blood cells
postoperatively in 2 patients. This occurred in patients
treated with only argon beam coagulation and thrombin-
soaked Surgicel.
Pathologic examination revealed a majority of low-grade
tumors and a significant amount of benign disease. Stud-
ies have shown that about 10% to 18% of small renal
masses are benign.4 Although intraoperative frozen sec-
tion of the tumor has been proposed as a means to
decrease the amount of benign lesions removed, the re-
sults to date are discouraging.16 With the increased diag-
nosis of incidental renal masses, a minimally invasive
approach is certainly of benefit given the substantial risk
of over treating a benign lesion.
Minimally invasive ablative approaches include cryoabla-
tion, radiofrequency ablation, and high-intensity focused
ultrasound. These can be done laparoscopically or percu-
taneoulsy. Histology, grade, and stage are important prog-
nostic indicators for renal cell cancer. An important limi-
tation of these techniques includes the lack of pathologic
specimens to allow accurate histologic evaluation. While
some advocates have biopsied these lesions preopera-
tively, needle biopsy of renal masses, even as performed
at the time of surgical removal, has shown a high nondi-
agnostic rate and low specificity, and its routine use is not
advocated.17 With ablative procedures, the margin status
is unknown. Long-term results are largely unknown. Suc-
cessful outcomes have been defined as radiographic evi-
dence of infarction, hemorrhage, reduction in size, or
absence of growth on follow-up.18 Gervais et al19 used
percutaneous radiofrequency ablation to treat 9 patients
with CT or ultrasound guidance. Four required repeat
treatment based on residual tumor on repeat imaging. The
best modality to both target and monitor therapy and to
follow-up treated lesions has yet to be established.20 With
these limitations for ablative procedures, the indications
for their clinical application in the treatment of the inci-
dentally found renal mass is yet to be defined.
CONCLUSION
Laparoscopic nephron-sparing surgery is feasible with a
low complication rate and is emerging as a viable option
in carefully selected patients. Benefits include shorter hos-
pitalization, decreased analgesia requirements, and more
rapid convalescence. Hilar control and renal surface hy-
pothermia, while technically more demanding, will even-
tually increase the application of the laparoscopic ap-
proach to more tumors by allowing treatment of centrally
located lesions. However, the current experience confirms
the ability to perform laparoscopic nephron-sparing sur-
gery for small, exophytic, peripherally located small tu-
mors, with a high degree of technical success and low
morbidity. If these lesions are exophytic and amenable to
partial nephrectomy with minimal parenchymal entry,
laparoscopic partial nephrectomy provides an attractive
approach and should be considered before ablative ap-
proaches in those patients with appropriate surgical risks.
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